ocular

Omidenepag isopropyl (DE-117) is a selective prostaglandin EP2 receptor agonist and a novel topical ocular blood pressure lowering compound.Omidenepag isopropyl has a weak affinity for EP1, EP2, and FP receptors.Omidenepag isopropyl is used in studies of glaucoma and hypertension. Omidenepag isopropyl can be used to study glaucoma and hypertension.

Bunazosin Hydrochloride (E 1015) is an alpha(1)-adrenoceptor antagonist used as a systemic antihypertensive and an ocular hypotensive drug.

Ot-730(QLT 091568)is a novel selective beta-blocker prodrug for the study of ocular diseases.

ot-730 HCl is a novel selective beta blocker prodrug for the study of ocular diseases.

PG-11047 2HCl is an apoptosis-stimulating agent used in the treatment of genitourinary disorders, immune system disorders, genetic disorders and malformations, ocular disorders, and disorders of the blood and lymphatic systems, and in the study of lymphomas and prostate cancer.

Tropicamide (Ro 1-7683) is a synthetic muscarinic antagonist with anticholinergic properties similar to atropine. Upon ocular administration, it binds to and blocks muscarinic receptors in the sphincter and ciliary muscles, inhibiting cholinergic responses and causing pupil dilation and ciliary muscle paralysis. Tropicamide is used as a diagnostic agent to induce short-duration mydriasis and cycloplegia.

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties. Upon ophthalmic administration, bromfenac binds to and inhibits cyclooxygenase II (COX II), an enzyme that converts arachidonic acid to cyclic endoperoxides, which are prostaglandin (PG) precursors. By inhibiting PG formation, bromfenac prevents PG-induced inflammation, vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, increased vascular permeability, and elevated intraocular pressure (IOP).

Difluprednate (Myser)(Durezol) is a corticosteroid, approved for the treatment of post-operative ocular inflammation and pain.

Emedastine (LY188695) is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. In addition, emedastine may also inhibit the late-phase allergic reaction mediated through leukotrienes or prostaglandins, or by producing an anti-platelet activating factor effect. Upon ocular administration, emedastine causes a dose-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva. Emedastine does not affect adrenergic, dopamine, or serotonin receptors.

Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.

Diquafosol Tetrasodium is a P2Y2 receptor agonist that stimulates the secretion of mucins from ocular tissues Diquafosol tetrasodium (INS365) improves tear film stability and visual function, as a topical treatment of dry eye disease.

Tetrahydrozoline (Tetryzoline), an alpha agonist, have an effect on the constriction of conjunctival blood vessels. This contributes to relieve the redness of the eye resulted from minor ocular irritants.

Methyl-4-oxoretinoate is a synthetic retinoid compound with anticancer compounds that can induce differentiation and apoptosis in cancer cells.Methyl-4-oxoretinoate is used in the treatment of acne, psoriasis, and other skin disorders.Methyl-4-oxoretinoate has the potential to be used in the treatment of a variety of ocular disorders such as age-related macular degeneration. related macular degeneration).

Naphazoline nitrate is an α1-Adrenergic receptor agonist. It also induces autophagy and necrotic cell death in erythroleukemia cells and inhibits erythroid differentiation. It used to treat congestion and ocular pathologies.

(E)-Alprenoxime, the isomer of Alprenoxime, is a site-activated ocular β-blocker.

Bimatoprost (AGN 192024) D5 is a deuterium-labeled Bimatoprost. Bimatoprost is a topical hypotensive agent frequently used for treating glaucoma and ocular hypertension.

Flavanone hydrazine is a potent non-steroidal anti-inflammatory agent that effectively inhibits lens protein–induced ocular inflammation.

(Rac)-MGV354 (MGV354) is the racemate of MGV354. MGV354 is a soluble activator of guanylate cyclase (sGC)(EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively).

Unoprostone is a prostaglandin F2α analogs (PGAs), and reduces intraocular pressure and is used topically for glaucoma or ocular hypertension.

Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). IC50 Value: Target: HCV Balapiravir was discontinued for safety reasons in 28-36% of patients (m

Latanoprostene bunod (LBN) is nitric oxide (NO)-donating prostaglandin F2a analog and is a topical ophthalmic therapeutic. It is used for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT).

Omidenepag (UR-7276) is a selective and potent prostaglandin E2 receptor 2 (EP2) agonist and a novel topical ocular hypotensive agent.Omidenepag is used in the study of glaucoma and hypertension.

Levobetaxolol, also known as AL-1577A and Betaxon, is a cardioselective β-adrenergic receptor inhibitor. It has been demonstrated to reduce intraocular pressure in patients affected by ocular hypertension and primary open-angle glaucoma.

Ketorolac (RS37619) hydrochloride is a nonsteroidal anti-inflammatory drug and a non-selective COX inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in a 0.5% ophthalmic solution format for the investigation of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and post-operative ocular inflammation pain. Additionally, Ketorolac hydrochloride serves as a DDX3 inhibitor, making it pertinent for research in cancer therapies.